This page lists the SEC filings reported by Broadfin Capital, LLC.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2018-02-13 | Broadfin Capital, LLC | ARATANA THERAPEUTICS, INC. | 4,294,426 | 10.0% | EDGAR |
| SC 13G/A | 2018-02-13 | Broadfin Capital, LLC | AVADEL PHARMACEUTICALS PLC | 2,591,721 | 6.5% | EDGAR |
| SC 13G/A | 2018-02-13 | Broadfin Capital, LLC | Regulus Therapeutics Inc. | 1,509,342 | 1.4% | EDGAR |
| SC 13G/A | 2018-02-13 | Broadfin Capital, LLC | BIODELIVERY SCIENCES INTERNATIONAL INC | 4,634,119 | 8.3% | EDGAR |
| SC 13G/A | 2018-02-13 | Broadfin Capital, LLC | TENAX THERAPEUTICS, INC. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2018-02-13 | Broadfin Capital, LLC | SCYNEXIS INC | 326,250 | 1.1% | EDGAR |
| SC 13G/A | 2018-02-13 | Broadfin Capital, LLC | CATALYST PHARMACEUTICALS, INC. | 7,097,300 | 6.9% | EDGAR |
| SC 13G/A | 2018-02-13 | Broadfin Capital, LLC | ANTARES PHARMA, INC. | 4,535,647 | 2.9% | EDGAR |
| SC 13G/A | 2018-02-13 | Broadfin Capital, LLC | Nexvet Biopharma plc | 0 | 0.0% | EDGAR |
| SC 13G/A | 2018-02-13 | Broadfin Capital, LLC | Aviragen Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2018-02-13 | Broadfin Capital, LLC | Cidara Therapeutics, Inc. | 857,397 | 4.2% | EDGAR |
| SC 13G/A | 2018-02-13 | Broadfin Capital, LLC | Mirati Therapeutics, Inc. | 2,447,746 | 8.9% | EDGAR |
| SC 13G/A | 2018-02-13 | Broadfin Capital, LLC | Aevi Genomic Medicine, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2018-02-13 | Broadfin Capital, LLC | HERON THERAPEUTICS, INC. /DE/ | 2,428,518 | 3.8% | EDGAR |
| SC 13G/A | 2018-02-13 | Broadfin Capital, LLC | Strongbridge Biopharma plc | 3,786,695 | 9.4% | EDGAR |
| SC 13G/A | 2018-02-13 | Broadfin Capital, LLC | VERACYTE, INC. | 746,358 | 2.2% | EDGAR |
| SC 13G/A | 2018-02-13 | Broadfin Capital, LLC | DURECT CORP | 0 | 0.0% | EDGAR |
| SC 13G/A | 2018-02-13 | Broadfin Capital, LLC | Ignyta, Inc. | 1,150,119 | 1.7% | EDGAR |
| SC 13G/A | 2018-02-13 | Broadfin Capital, LLC | Alphatec Holdings, Inc. | 145,514 | 0.9% | EDGAR |
| SC 13G/A | 2018-02-13 | Broadfin Capital, LLC | Corium International, Inc. | 3,432,326 | 9.5% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.